The technology appraisal specifies that dimethyl fumarate should not be used in patients with highly active or rapidly-evolving severe RRMS and that the manufacturer must provide the drug with the discount agreed in the patient access scheme. RRMS is normally defined as two clinically significant relapses in the previous two years.
Register or Subscribe to MIMSGPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.
MIMS bulletinsNews and updates straight to your inbox.
Prescribing Update: Fortnightly news bulletin
Alert: Urgent prescribing updates
Spotlight: Disease-themed monthly round-up
Read the latest issue online exclusively on MIMS Learning.
Handy calculators and conversions for primary care.